'Global Stem Cell Technology' (GST) develops stem cell therapies for the treatment of orthopedic and metabolic diseases in animals. Within Europe, the company was the first to obtain authorization to market veterinary medicines based on stem cells worldwide. Along with an investment by Participatie Maatschappij Vlaanderen (PMV), GST was incorporated into the Anacura group of Griet Nuytinck in 2014. “This was more than a financial investment in a startup,” explains Nuytinck. “We offered GST support from an experienced biotech business environment, at a time when stem cell therapy was still an unexplored and unclear area.”
Thanks to its deep commitment to developing effective and standardized products and with the logistical support of Boehringer Ingelheim, GST became a forerunner in its field. “The recent takeover opens up possibilities for developing and selling new stem cell products all over the world,” ascertains Nuytinck. According to Jean-Luc Michel, head of Global Strategic Marketing at Boehringer Ingelheim, GST’s expertise and state-of-the-art products will enable the firm to offer even more innovative solutions to customers.
Nuytinck is thrilled with the news of the acquisition. She is convinced that GST CEO Jan Spaas and his team will be given every opportunity to develop their stem cell platform within their new professional environment. “Furthermore, we will continue to embed innovative stem cell research in our laboratories in Flanders.” Roderick Verhelst, senior investment manager at PMV and director of GST adds: “It’s a strong recognition of Flanders' position as a global biotech leader.”